A randomized trial of rectal indomethacin to prevent post-ERCP pancreatitis.
By B. Elmunzer, J. Scheiman, G. Lehman, P. Mosler, P. Higgins, Rodney A. Hayward, J. Romagnuolo, G. Elta, S. Sherman, A. Waljee and 21 more. New England Journal of Medicine, 2012
685 citations recorded by the source corpus.
Subfields: Pulmonary and Respiratory Medicine, Surgery
View Paper: https://www.semanticscholar.org/paper/85dc6194c3000e2cf9f7b1cb6a3b48e6f0fb4a6d
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
- J. Dumonceau
- C. Kapral
- Amit G. Singal
- L. Aabakken
- I. Papanikolaou
- P. Higgins
- A. Tringali
- A. Waljee
Citations in the corpus
- ERCP-related adverse events: European Society of Gastrointestinal Endoscopy (ESGE) Guideline (2019, methodology): “[6]; it has been used in most large clinical trials, though with small variations in the minimum duration of hospital stay [7], the time at which pancreatic enzymes are measured [8] and their minimum elevation for diagnosis [9].”
- A Primer on Effectiveness and Efficacy Trials (2014, background): “only high-risk patients, such as those with sphincter of Oddi dysfunction, were included.(19) Effectiveness studies would help clarify if these results can be generalized to lowrisk and medium-risk patients undergoing ERCP in everyday”